SurModics Acquires Drug Delivery Assets From PR Pharmaceuticals
Posted on: Wednesday, 5 November 2008, 09:00 CST
SurModics, a provider of surface modification and drug delivery technologies to the healthcare industry, has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, a drug delivery company specializing in injectable, biodegradable sustained release formulations.
SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. The acquisition is expected to be accretive to SurModics's fiscal 2009 earnings, excluding any one-time charges related to the acquisition.
The proprietary technologies acquired from PR Pharmaceuticals have broad applicability and address key needs, enabling the delivery of injectable drugs, including proteins, using biodegradable microparticles through smaller diameter needles compared to competing technologies.
In addition to the intellectual property being acquired, SurModics will be assuming responsibility for several customer-paid development projects currently in progress with pharmaceutical and biotechnology companies, including Jerini Ophthalmic.
Finally, SurModics will be the paid development partner for PR Pharmaceuticals's proprietary product called InsuLAR, a once-a-week sustained release formulation of basal insulin for the diabetes marketplace.
Bruce Barclay, president and CEO of SurModics, said: "The proprietary technologies and existing business we are acquiring from PR Pharmaceuticals are a perfect fit for SurModics. The proprietary technologies complement and enhance the existing portfolio of drug delivery capabilities available from SurModics and Brookwood. Further, with the addition of these new technologies, SurModics is poised to drive customer programs and long-term revenue even more effectively."
Source: Datamonitor
Related Articles
- Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on Its Proprietary Drug Delivery Platform
- MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
- Kurve Technology Launches Nasal Drug Delivery Blog
- Lipomics Technologies to Support Isis Pharmaceuticals in Preclinical and Clinical Studies of Metabolic Drug Candidates
- Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery
- AerovectRx Corp. Receives FDA 510(K) Clearance for the First Nebulizer Drug Delivery System With Disposable Medication Cartridge; AeroCell(TM) Cartridge Provides for Cost-Effective Delivery of Drugs and Ongoing Revenue Stream
- Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and Other Assets
- Professor Developing New Strategies for Delivery of Drugs to Fight, Treat Tuberculosis
- Teva Pharmaceutical to Acquire IVAX Corporation for 3.73 Times Revenue
- Genaissance Pharmaceuticals and Ipsogen to Offer Comprehensive Package of Pharmacogenomic Technologies for Oncology Drug Development
 |
 |
User Comments (0)
RSS Feeds